DE69418699D1 - Induktion der antworten zytotoxischer t-lymphozyten - Google Patents

Induktion der antworten zytotoxischer t-lymphozyten

Info

Publication number
DE69418699D1
DE69418699D1 DE69418699T DE69418699T DE69418699D1 DE 69418699 D1 DE69418699 D1 DE 69418699D1 DE 69418699 T DE69418699 T DE 69418699T DE 69418699 T DE69418699 T DE 69418699T DE 69418699 D1 DE69418699 D1 DE 69418699D1
Authority
DE
Germany
Prior art keywords
replicating
mammalian host
protein antigen
methods
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69418699T
Other languages
English (en)
Other versions
DE69418699T2 (de
Inventor
Kenneth Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE69418699D1 publication Critical patent/DE69418699D1/de
Publication of DE69418699T2 publication Critical patent/DE69418699T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical
DE69418699T 1993-01-11 1994-01-10 Induktion der antworten zytotoxischer t-lymphozyten Expired - Lifetime DE69418699T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US323393A 1993-01-11 1993-01-11
PCT/US1994/000362 WO1994015635A1 (en) 1993-01-11 1994-01-10 Inducing cytotoxic t lymphocyte responses

Publications (2)

Publication Number Publication Date
DE69418699D1 true DE69418699D1 (de) 1999-07-01
DE69418699T2 DE69418699T2 (de) 1999-09-30

Family

ID=21704843

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69418699T Expired - Lifetime DE69418699T2 (de) 1993-01-11 1994-01-10 Induktion der antworten zytotoxischer t-lymphozyten

Country Status (11)

Country Link
US (2) US5928647A (de)
EP (1) EP0678034B1 (de)
JP (1) JPH08505625A (de)
AT (1) ATE180407T1 (de)
AU (1) AU679041B2 (de)
CA (1) CA2153391C (de)
DE (1) DE69418699T2 (de)
DK (1) DK0678034T3 (de)
ES (1) ES2131676T3 (de)
GR (1) GR3030568T3 (de)
WO (1) WO1994015635A1 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100372375B1 (ko) * 1993-12-23 2003-04-21 머클한스피터 면역반응의강화방법
DK0789590T3 (da) * 1994-09-23 2002-11-04 Zonagen Inc Chitosaninduceret immunforstærkning
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1323346B1 (de) * 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Rezeptorspezifischer Transepithelealer Transport von Immunogenen
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DE19511276C2 (de) * 1995-03-27 1999-02-18 Immuno Ag Adjuvans auf der Basis kolloidaler Eisenverbindungen
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
EP1275380A1 (de) * 1997-01-30 2003-01-15 Chiron Corporation Verwendung von Mikropartikeln mit adsorbiertem Antigen zur Stimulierung der Immunabwehr
ATE235890T1 (de) 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6254890B1 (en) * 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EP1221968B1 (de) * 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Verfahren zur erhaltung zellimmuneantworten gegen proteinen
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001245552A1 (en) * 2000-03-09 2001-09-17 Emory University Transcutaneous immunization for large particulate antigens
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CN101428006A (zh) 2000-09-28 2009-05-13 诺华疫苗和诊断公司 微粒体组合物及其生产方法
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030108565A1 (en) 2001-07-10 2003-06-12 Johnson Mark E. Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US20030219442A1 (en) * 2002-03-13 2003-11-27 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US20040170606A1 (en) * 2002-06-07 2004-09-02 Palmer Kenneth E. Production of peptides in plants as viral coat protein fusions
EP1545625B1 (de) 2002-06-07 2011-08-24 Kentucky Bioprocessing, LLC Flexlibler aufbau- und darreichungs-plattform von impfstoffen
BR0311995A (pt) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
EP2351770A1 (de) * 2002-07-17 2011-08-03 Cytos Biotechnology AG Molekulare Antigen-Anordnung durch Verwendung eines Virus ähnlichen Partikels vom Virus ap205
EP1523334A2 (de) * 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-träger-konjugate und ihre verwendung
CA2492930C (en) * 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
WO2004100984A1 (en) * 2003-05-13 2004-11-25 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
EP2591786B1 (de) * 2003-10-16 2017-04-12 Cancure Limited Immunmodulierende Zusammensetzungen und ihre Verwendung
JP2007518762A (ja) * 2004-01-20 2007-07-12 サイトス バイオテクノロジー アーゲー グレリン−担体結合体
EP2497831B1 (de) 2004-05-25 2014-07-16 Oregon Health and Science University TB-Impfung unter Verwendung von Impfvektoren auf HCMV-Basis
US7572451B2 (en) * 2004-10-25 2009-08-11 Cytos Biotechnology Ag Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
JP5164830B2 (ja) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
EP2010226B1 (de) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
WO2007133807A2 (en) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP5391387B2 (ja) * 2007-03-09 2014-01-15 小川 一文 磁気感応性薬剤およびその製造方法
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
US10736848B2 (en) 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
US8268887B2 (en) 2008-10-08 2012-09-18 Feng Xu Drug conjugates and methods of use thereof
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
AU2010254550B2 (en) 2009-05-27 2015-10-15 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
EP2470554B1 (de) * 2009-08-26 2017-06-28 Selecta Biosciences, Inc. Zusammensetzungen zur induzierung von t-zellen-hilfe
ES2538007T3 (es) 2009-09-16 2015-06-16 Vaxart, Inc. Estrategia de inmunización para prevenir una infección por H1N1
KR101773636B1 (ko) 2009-11-19 2017-09-01 솔리스 바이오다인 폴리펩티드 안정성 및 활성을 증가시키는 조성물 및 관련된 방법
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
AU2011258156B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
WO2012018387A2 (en) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
KR101930106B1 (ko) 2011-03-08 2018-12-17 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절자
WO2012149393A2 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
AU2012290306B2 (en) 2011-07-29 2017-08-17 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
US10221454B2 (en) 2011-10-10 2019-03-05 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
WO2013067451A2 (en) 2011-11-04 2013-05-10 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
EP2812452B1 (de) 2012-02-09 2020-05-27 Population Bio, Inc. Verfahren und zusammensetzungen zum screening und zur behandlung von entwicklungsstörungen
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
CN105407728A (zh) 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和系统
ES2841137T3 (es) 2013-12-20 2021-07-07 Sagimet Biosciences Inc Moduladores heterocíclicos de la síntesis de lípidos y combinaciones de los mismos
AU2015204907B2 (en) 2014-01-07 2018-08-02 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
JP6797692B2 (ja) 2014-02-20 2020-12-09 バクサート インコーポレイテッド 小腸送達のための製剤
ES2868305T3 (es) 2014-03-28 2021-10-21 Univ Washington Through Its Center For Commercialization Vacunas contra el cáncer de mama y de ovario
EP3169699A4 (de) 2014-07-18 2018-06-20 The University of Washington Krebsimpfstoffzusammensetzungen und verfahren zur verwendung davon
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
EP3212001A4 (de) 2014-10-31 2018-04-25 Whole Biome Inc. Verfahren und zusammensetzungen im zusammenhang mit mikrobieller behandlung und diagnose von störungen
JP6758314B2 (ja) 2015-03-19 2020-09-23 サギメット バイオサイエンシーズ インコーポレイテッド 脂質合成の複素環式調節因子
US11433146B2 (en) 2015-06-12 2022-09-06 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
JP2019527065A (ja) 2016-05-04 2019-09-26 アビリタ バイオ，インク． 複数膜貫通型タンパク質を調製する方法とプラットフォーム
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US11725232B2 (en) 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP3675882A4 (de) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit mikrobiomen
SG11202012044QA (en) 2018-06-29 2021-01-28 Wuhan Neurophth Biological Tech Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
EP4177356A1 (de) 2018-08-08 2023-05-10 PML Screening, LLC Verfahren zur beurteilung des risikos der entwicklung einer viruserkrankung unter verwendung eines genetischen tests
CN112584874A (zh) 2018-08-20 2021-03-30 武汉纽福斯生物科技有限公司 用于治疗莱伯氏遗传性视神经病变的组合物和方法
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
EP4013788A1 (de) 2019-08-12 2022-06-22 Purinomia Biotech, Inc. Verfahren und zusammensetzungen zur förderung und verstärkung von t-zell-vermittelten immunantworten durch adcc-targeting von cd39-exprimierenden zellen
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CN113025633A (zh) 2019-12-09 2021-06-25 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
CN115927472A (zh) 2021-07-05 2023-04-07 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
WO2023011632A1 (zh) 2021-08-06 2023-02-09 武汉纽福斯生物科技有限公司 用于治疗由于nd4突变造成的莱伯氏遗传性视神经病变的组合物和方法
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4804624A (en) * 1982-05-21 1989-02-14 The University Of Tennessee Research Corporation Passive agglutination assay for pseudorabies antibody
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
GB2160312B (en) 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US5078998A (en) 1985-08-02 1992-01-07 Bevan Michael J Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen
GB8610983D0 (en) 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US5194254A (en) 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US5041385A (en) 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5008116A (en) 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
WO1990007322A1 (en) 1988-12-19 1990-07-12 David Gordon Diagnosis and treatment of viral effects
US5021551A (en) 1989-01-18 1991-06-04 Washington University Method of enhancing peptide immunogenicity
US5045320A (en) * 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
JPH05506447A (ja) * 1990-05-10 1993-09-22 ザ　ダナーファーバー　キャンサー　インスチチュート β↓２―ミクログロブリンを伴い抗原供給細胞表面上で外来ペプチッドのクラスＩＭＨＣ分子との会合を増進させる方法
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
AU8303691A (en) 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
AU2185592A (en) 1991-06-06 1993-01-08 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
FR2682114B1 (fr) * 1991-10-03 1996-02-23 Pasteur Merieux Serums Vacc Vaccin de sous-unite contre les infections a neisseria meningitidis et sous-unites correspondantes a l'etat purifie.
ES2171410T3 (es) 1991-11-26 2002-09-16 Jenner Technologies Vacunas antitumorales.

Also Published As

Publication number Publication date
CA2153391A1 (en) 1994-07-21
JPH08505625A (ja) 1996-06-18
CA2153391C (en) 2000-08-15
DE69418699T2 (de) 1999-09-30
GR3030568T3 (en) 1999-10-29
WO1994015635A1 (en) 1994-07-21
ATE180407T1 (de) 1999-06-15
AU679041B2 (en) 1997-06-19
EP0678034B1 (de) 1999-05-26
ES2131676T3 (es) 1999-08-01
AU6086594A (en) 1994-08-15
US6328972B1 (en) 2001-12-11
DK0678034T3 (da) 1999-11-08
US5928647A (en) 1999-07-27
EP0678034A1 (de) 1995-10-25

Similar Documents

Publication Publication Date Title
DE69418699T2 (de) Induktion der antworten zytotoxischer t-lymphozyten
Feng et al. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity
CA2123580A1 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GR3015791T3 (en) Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
ATE286744T1 (de) Stress protein peptid komplexe als prophylaktische und therapeutische impfstoffe gegen intrazelluläre pathogene
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
GB2255093A (en) Hiv-1 core protein fragments
EP0634937A1 (de) Impfstoffe die nicht ionische tensid vesikeln enthalften.
CA2001328A1 (en) Borrelia antigen
NZ326092A (en) Immunostimulatory composition and method
DE69930630D1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
DE69110877T2 (de) Idiotypen-impfung gegen b-zell-lymphoma.
CA2055615A1 (en) Monoclonal antibodies for inducing tolerance
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
EP0531401A4 (en) Enhancing the association of exogenous peptides with class i mhc molecules on immune system cells
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
Lees et al. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
WO2001059073A3 (en) Cytotoxic t lymphocytes activated by dendritic cell hybrids
IL92009A0 (en) Cell lines,monoclonal anti-bodies and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition